Glimepiride Sandoz (Glimepiride)

Glimepiride Sandoz is indicated for the management of hyperglycemia in patients with type 2 diabetes mellitus, usually when diet, exercise, and other non‑pharmacologic measures are insufficient.

• As monotherapy in patients who have not achieved glycemic targets with lifestyle changes alone.
• In combination with metformin when additional glucose lowering is needed.
• As part of a fixed‑dose combination with other oral antidiabetics, if prescribed.
• For patients with preserved pancreatic beta‑cell function who require insulin secretagogue therapy.
• To be used under medical supervision as part of an individualized diabetes care plan.

The safety profile of Glimepiride Sandoz includes a range of adverse events that vary in frequency and severity.

Common

• Hypoglycemia, especially when meals are missed or delayed.
• Nausea or mild gastrointestinal discomfort.
• Weight gain due to increased insulin activity.
• Headache or dizziness.

Serious

• Severe hypoglycemia requiring assistance.
• Allergic reactions such as rash, pruritus, or angioedema.
• Hemolytic anemia or other blood dyscrasias.
• Liver dysfunction or hepatitis.
• Acute pancreatitis.

Before starting Glimepiride Sandoz, healthcare providers should evaluate several clinical factors to minimize risks.

• Assess renal and hepatic function, as impairment may affect drug clearance.
• Review history of hypoglycemia or adrenal insufficiency.
• Use caution in elderly patients due to increased sensitivity.
• Avoid use during pregnancy and breastfeeding unless benefits outweigh risks.
• Monitor blood glucose regularly to adjust dose appropriately.
• Consider cardiovascular status, as sulfonylureas may affect cardiac ischemic preconditioning.

Glimepiride Sandoz can interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse reactions.

Avoid

• Concurrent use with other sulfonylureas or meglitinides (additive hypoglycemia risk).
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that raise glimepiride levels.
• MAO‑B inhibitors (e.g., selegiline) which may potentiate hypoglycemia.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Thiazide diuretics, which can increase blood glucose.
• Corticosteroids, which may reduce glimepiride efficacy.